Tempus AI, Inc (TEM)

NASDAQ: TEM · Real-Time Price · USD
31.83
-0.51 (-1.58%)
At close: Jan 14, 2025, 4:00 PM
32.32
+0.49 (1.54%)
Pre-market: Jan 15, 2025, 6:16 AM EST
-1.58%
Market Cap 5.01B
Revenue (ttm) 640.44M
Net Income (ttm) -800.71M
Shares Out 157.45M
EPS (ttm) -8.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,997,652
Open 33.10
Previous Close 32.34
Day's Range 31.67 - 34.62
52-Week Range 22.89 - 79.49
Beta n/a
Analysts Buy
Price Target 57.20 (+79.71%)
Earnings Date Feb 17, 2025

About TEM

Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to ph... [Read more]

Sector Healthcare
IPO Date Jun 14, 2024
Employees 1,952
Stock Exchange NASDAQ
Ticker Symbol TEM
Full Company Profile

Financial Performance

In 2023, Tempus AI's revenue was $531.82 million, an increase of 65.85% compared to the previous year's $320.67 million. Losses were -$265.96 million, -20.35% less than in 2022.

Financial numbers in USD Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for TEM stock is "Buy." The 12-month stock price forecast is $57.2, which is an increase of 79.71% from the latest price.

Price Target
$57.2
(79.71% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Tempus AI: Disappointing Q4 Preliminary Results, But Bullish Fundamental Update

Tempus AI is a leading player in healthcare AI, aiming to deliver personalized treatment suggestions through its proprietary data model. Preliminary Q4 results and 2025 guidance show mixed performance...

1 hour ago - Seeking Alpha

Tempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical Care

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today introduced a suite of new, transformative...

22 hours ago - Business Wire

Tempus Announces Its First-Ever, Whole-Genome Sequencing Assay, xH

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its f...

1 day ago - Business Wire

Tempus Announces Preliminary Fourth Quarter and Full Year 2024 Results

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited ...

1 day ago - Business Wire

Tempus Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, ...

6 days ago - Business Wire

Tempus to Present at 43rd Annual J.P. Morgan Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the 43rd Annual J.P. Morgan...

7 days ago - Business Wire

Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown

It's been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling from the aftermath. According to a CNBC analysis of 39 public digital health com...

21 days ago - CNBC

Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions

CHICAGO--(BUSINESS WIRE)--Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network ...

27 days ago - Business Wire

Tempus AI: Recent Weakness Presents Gift Ahead Of The Holidays

Tempus AI has strong long-term potential in healthcare technology, despite recent stock volatility due to lock-up period expiration and insider selling. The company's innovative "Intelligent Diagnosti...

4 weeks ago - Seeking Alpha

New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by...

4 weeks ago - Business Wire

Personalis and Tempus Expand Collaboration to Biopharma

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed...

Other symbols: PSNL
4 weeks ago - Business Wire

Tempus AI: Why I'm Buying This AI Stock

Tempus AI's strategic acquisitions and partnerships, including Ambry Genetics and a JV with SoftBank, bolster its growth and competitive edge in AI health tech. The revenue growth and gross margins fo...

5 weeks ago - Seeking Alpha

Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Piper Sandler 36th Annu...

7 weeks ago - Business Wire

The Big 3: CRWD, CVNA, TEM

@ProsperTradingAcademy's Charles Moon is bullish on all of today's Big 3. He points to Crowdstrike's (CRWD) recovery and Carvana (CVNA) coiling to the upside as positive markers but warns of volatilit...

Other symbols: CRWDCVNA
7 weeks ago - Schwab Network

Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven Innovation

Tempus AI, Inc. founded in 2015, leverages AI for precision medicine, showing strong growth since its June 2024 listing, presenting a buying opportunity. The company boasts a vast clinical and molecul...

2 months ago - Seeking Alpha

Tempus Molecular Profiling Integration Now Available Through Flatiron's OncoEMR®

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron...

2 months ago - Business Wire

Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Acti...

2 months ago - Business Wire

Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript

Tempus AI, Inc. (NASDAQ:TEM) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Liz Krutoholow – Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer...

2 months ago - Seeking Alpha

Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted fo...

2 months ago - Business Wire

Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its Immu...

2 months ago - Business Wire

Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...

2 months ago - Business Wire

Tempus to Report Third Quarter 2024 Financial Results on November 4

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday,...

2 months ago - Business Wire

Tempus and Northwestern Medicine Announce Collaboration to Bring Practical Application of AI to Healthcare

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, and Northwestern Medicine, Chicago's premier integrated academic health system, today announced a collabor...

2 months ago - Business Wire

Tempus: Attempting To Lead The AI Revolution In Healthcare

Tempus AI, Inc, a healthcare technology company, has shown DECENT gains since its listing in June, outperforming the Nasdaq and AI-themed stock portfolios. TEM aims to leverage AI and ML and revolutio...

2 months ago - Seeking Alpha

Tempus to Report Third Quarter 2024 Financial Results on November 7

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursda...

2 months ago - Business Wire